Alexandria Real Estate Equities, Inc. Reports 3Q26 and YTD 3Q26 Net Loss per Share - Diluted of $3.74 and $2.06, respectively, and 3Q26 and YTD 3Q26 FFO per Share - Diluted, as Adjusted, of $1.54 and $5.00, respectively

Alexandria Real Estate reported a 3Q26 net loss attributable to common stockholders of $638.5 million, or $3.74 per diluted share, including $637.9 million in real estate impairment charges; adjusted FFO fell to $1.54 per share from $2.22 a year earlier. Same-property NOI declined 6.7%, and operating occupancy was 87.1%, though quarterly leasing volume reached 1.24 million RSF and 99.9% of rents and receivables were collected. The company maintained 2026 adjusted FFO guidance at $6.38–$6.42 per share, while citing tenant wind-downs, lease expirations and expected negative 2027 NOI performance; it reported $4.56 billion of liquidity and $2.62 billion in completed or pending asset-sale proceeds.

Analysis

The impairment is non-cash for current FFO, but it is a more important signal about residual values: several assets no longer justify the capital required to convert or lease them as labs. That weakens the assumption that Alexandria can readily recycle non-core space at attractive values. The counterweight is strategic: selling or pivoting those projects limits future capital commitments and may leave better-capitalized megacampus owners with less competing lab supply over time.

Near term, the reported leasing rebound is not yet an operating inflection. Same-property NOI remains negative, renewal/re-leasing spreads are still below zero, and management expects 2027 downtime from large expirations and possible tenant wind-downs. Executed future leases and deliveries can support 2028 recovery, but depend on tenant improvements, occupancy timing, and successful lease-up. The maintained 2026 FFO midpoint therefore masks a weaker near-term operating trajectory rather than confirming a turn.

Credit is the key equity constraint: leverage remains elevated versus the stated year-end target, fixed-charge coverage guidance was reduced, and a portion of the balance-sheet support comes from high-coupon junior subordinated notes. Asset-sale proceeds can bridge funding needs, but the $2.62bn pipeline includes late-stage negotiations, not just closed transactions. The Campus Point stake sale adds liquidity while Alexandria retains control and expects to fund most future construction, limiting the apparent risk transfer.

Consensus may over-focus on the impairment and miss the benefit of cancelled or cheaper projects; however, the more immediate risk is that asset recycling and tenant recovery take longer than planned. The October 27 call and December 2 Investor Day are near-term catalysts for disposition certainty, 2027 occupancy, and construction-spend details.

Key Decisions for Investors

• Keep ARE underweight versus a diversified REIT benchmark rather than make an outright short on the impairment alone. The downside case is continued negative same-property NOI plus delayed transactions; reassess if management provides credible evidence of improving occupancy and leasing economics.
• Treat the $2.62bn disposition pipeline as a watch item, not committed liquidity. Track closings, proceeds versus carrying values, and whether 2027 capital needs require additional asset sales or debt; slippage or material price concessions would weaken the equity and credit thesis.
• On the October 27 call and December 2 Investor Day, focus on 2027 lease expirations/downtime, tenant wind-down exposure, fixed-charge coverage, and construction funding. Falsification of the cautious thesis would be improving same-property NOI and occupancy alongside completed sales without deterioration in leverage targets.
• Do not infer a material NVO investment signal from its leased delivery: verify actual occupancy and rent commencement before treating deliveries as incremental cash-flow support for ARE.